Six of eight response-evaluable patients with urothelial carcinoma achieved partial responses on TJ101 in Phase I data presented at ESMO 2026, a 75% response rate that carries particular weight because those patients had already received enfortumab vedotin and pembrolizumab, a combination increasingly used in earlier lines of therapy. Activity after that regimen is exactly the gap the field has struggled to fill, and Phrontline Biopharma is betting a bispecific ADC design can reach it.
TJ101 targets both EGFR and B7-H3 on the same molecule, pairing those dual antibody arms with a topoisomerase I inhibitor payload. The rationale for hitting two antigens simultaneously is tumor heterogeneity: cells that downregulate one target may still express the other, which is one way ADCs that target a single antigen lose their grip in pretreated populations. Beyond urothelial carcinoma, the Phase I data showed early antitumor activity in squamous non-small cell lung cancer, small cell lung cancer, and prostate cancer, though patient numbers across those cohorts are not specified in the release. Phrontline also announced that Phase Ib has opened, with the first patient dosed.
The Phase Ib move matters for reading the safety picture. Dose escalation is still ongoing, and the company is exploring alternative schedules alongside dose increases, which suggests the team is working through tolerability questions rather than having resolved them. The source describes the safety profile as “emerging,” an honest label for a program this early. Bispecific ADCs carry the overlapping liability of both antibody targets and the payload, and how that profile holds at Phase Ib doses will shape whether the cross-tumor activity seen here translates into a registrational strategy.
The urothelial cohort is the cleanest signal to track. Responses after enfortumab vedotin-based therapy are hard to generate, and 75% in eight evaluable patients, while a small number, is an attention-holding rate. What Phase Ib does to that number, and whether the safety profile allows dose levels high enough to sustain it, is the question this program now has to answer.
TJ101: the facts in one place
- Also written: TJ-101, TJ 101
- Sponsor: Phrontline Biopharma
- Mechanism: Bispecific antibody-drug conjugate targeting EGFR and B7-H3 with topoisomerase I inhibitor payload (PY-4CAR2)
- Indication studied: Advanced solid tumors including urothelial carcinoma, squamous non-small cell lung cancer, small cell lung cancer, and prostate cancer
- Phase: Phase I / Phase Ib
- Primary endpoint: Safety, tolerability, pharmacokinetics, and preliminary antitumor activity; determination of maximum tolerated dose and recommended dose for expansion
- Headline result: 6 of 8 response-evaluable urothelial carcinoma patients achieved partial responses (75% response rate) in preliminary Phase I data presented at ESMO 2026
- Registry identifier: NCT07181473
- Current status: Not approved by any regulatory authority; Phase Ib initiated with first patient dosed October 29, 2026
- FDA IND approval: April 24, 2025
- Preliminary Phase I data presented at ESMO Congress 2026: October 23, 2026
- Phase Ib first patient dosed: October 29, 2026
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
